News - Diovan

Filter

Current filters:

Diovan

Popular Filters

Japan to investigate Novartis promotion of Diovan; US allegation over Exjade

Japan to investigate Novartis promotion of Diovan; US allegation over Exjade

10-01-2014

Swiss drug major Novartis faced two problems yesterday, when the Japanese Ministry of Health Labor and…

Asia-PacificCardio-vascularDiovanExjadeHematologyLegalMarkets & MarketingNorth AmericaNovartisPharmaceuticalUSA

Novartis third quarter results driven by strong sales despite generic competition

Novartis third quarter results driven by strong sales despite generic competition

22-10-2013

Novartis has announced strong sales performance in its third quarter results, released today.

DiovanEuropeFinancialNorth AmericaNovartisPharmaceuticalSandozZometa

Japanese lawmakers are stepping in to Diovan investigation

07-10-2013

Members of Japan’s Diet (Congressmen) have formed a bipartisan study group to examine Swiss drug major…

Asia-PacificCardio-vascularDiovanNovartisPharmaceuticalPoliticsRegulationResearch

Japan's MHLW approves 367 generics, but what does this mean?

21-08-2013

Japan's Ministry of Health Labor and Welfare (MHLW) approved 367 items of generic drugs last week. Launch…

Asia-PacificDiovanGenericsNovartisPharmaceuticalPricingRegulation

Novartis' research study questioned in Japan

15-07-2013

Swiss drug major Novartis (NOVN: VX) has admitted that there was an undisclosed conflict of interest…

Asia-PacificCardio-vascularDiovanNovartisPharmaceuticalResearch

Forest Lab's nebivolol and valsartan combo performs well in Ph III hypertension trial

28-06-2013

US drugmaker Forest Laboratories (NYSE:FRX) has announced positive top-line results from an eight-week…

BystolicCardio-vascularDiovanForest LaboratoriesnebivololPharmaceuticalResearchvalsartan

Overview of Novartis' patent losses from GlobalData

11-10-2012

Swiss drug major Novartis (NOVN: VX) is the latest victim of patent protection loss, note analysts at…

DiovanFemaraFinancialGleevecNovartisPatentsPharmaceuticalReclastZometa

Takeda's Edarbi set to be gold standard for hypertension

06-03-2012

Based on clinical data and the opinions of interviewed thought leaders, Edarbi (azilsartan medoxomil),…

Cardio-vascularDiovanEdarbiGlobalMarkets & MarketingNovartisPharmaceuticalTakeda Pharmaceuticals

Novartis cuts jobs, takes $1.22 billion charges

13-01-2012

In anticipation of the blockbuster antihypertensive Diovan’s (valsartan) patent expiration and an…

DiovanFinancialManagementNovartisPatentsPharmaceuticalRasilezTekturna

Actavis debuts generic Diovan in major European markets

20-11-2011

Iceland-headquartered generic drug major Actavis Group revealed on Friday that it has launched Valsartan…

ActavisCardio-vascularDiovanDiovan HCTEuropeGenericsMarkets & MarketingNovartisvalsartan

Back to top